Abzena vs Catalent: CDMO Comparison
Side-by-side comparison of Abzena and Catalent on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Catalent has more FDA inspections on record (11 vs 0) — a deeper regulatory paper trail.
- Catalent has 2 FDA warning letters on record; Abzena has none.
- Catalent holds 19 active EMA GMP certificates; Abzena does not appear in EudraGMDP.
- Catalent maintains 16 MHRA / UK GMP certificates; Abzena does not.
- Composite Signal Score: Catalent 76/100 vs Abzena 64/100 — a 12-point gap reflecting the combined quality, capacity and financial signal.
On a 13-modality CDMO landscape, both Abzena and Catalent qualify as ADC manufacturers; Catalent carries the higher composite Signal Score for ADC programs in this comparison.
What to evaluate for ADC programs
Both Abzena and Catalent qualify as ADC CDMOs. When choosing between them for ADC programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
HPAPI containment
Look for OEB-5 (sub-microgram occupational exposure band) suites for handling cytotoxic payloads end-to-end. Containment maturity is the floor for credible commercial ADC work.
Linker-payload chemistry on file
Match the CDMO's payload + linker experience to your program. MMAE / vc-MMAE is the most common; PBDs, calicheamicin, Dxd-class topoI inhibitors, and TLR agonists each carry distinct handling and analytical demands.
Commercial bioconjugation track record
Has the CDMO conjugated a commercially-approved ADC? Track record on Polivy, Padcev, Trodelvy, Enhertu, Tivdak, Elahere, Adcetris, Mylotarg, Besponsa, Lumoxiti, Blenrep, etc. is a strong qualifying signal.
Integrated DS + DP
Bioconjugation produces ADC drug substance; you'll also need sterile fill-finish for drug product. Confirm whether the CDMO covers both or partners — both routes work, but integrated is faster on transfer.
Frequently asked: Abzena vs Catalent
Which has the stronger FDA inspection record, Abzena or Catalent?
Abzena has 0 FDA inspections on record (NAI 0 / VAI 0 / OAI 0) and 0 warning letters. Catalent has 11 FDA inspections on record (NAI 3 / VAI 7 / OAI 1) and 2 warning letters.
How do Abzena and Catalent compare on European GMP coverage?
Abzena holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Catalent holds 19 active EMA GMP certificates and 16 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for ADC manufacturing — Abzena or Catalent?
Both Abzena and Catalent are tagged as ADC CDMOs in our directory, so both are credible options for ADC programs. The most important differentiator for ADC selection is typically hpapi containment: Look for OEB-5 (sub-microgram occupational exposure band) suites for handling cytotoxic payloads end-to-end. Containment maturity is the floor for credible commercial ADC work. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Abzena carries a Signal Score of 64/100 and Catalent carries 76/100 — a meaningful lead for Catalent. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →